Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals, Inc. today announced the presentation of preclinical data on ponatinib (Iclusig) , at the American Association for Cancer Research Annual Meeting 2013, in Washington.

9 Apr 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.

9 Apr 2013

Patent covering methods of treating ALS receives notice of allowance

Neuralstem, Inc. announced today that it received a notice of allowance for patent application 12/404,841. This patent covers methods for treating amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) with expanded spinal cord stem cells, including NSI-566.

6 Apr 2013

NeuroBlate Thermal Therapy System safe for treating recurrent glioblastoma, study shows

The first-in-human study of the NeuroBlate Thermal Therapy System finds that it appears to provide a new, safe and minimally invasive procedure for treating recurrent glioblastoma, a malignant type of brain tumor.

6 Apr 2013

Research reveals immortality gene mutation plays pivotal role in brain tumors, other cancers

Newly identified mutations in a gene that makes cells immortal appear to play a pivotal role in three of the most common types of brain tumors, as well as cancers of the liver, tongue and urinary tract, according to research led by Duke Cancer Institute.

19 Mar 2013

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Diffusion Pharmaceuticals LLC today announced completion of enrollment in a Phase II clinical trial of trans sodium crocetinate, its lead compound for the treatment of cancer.

15 Mar 2013

Stem cells from patient’s own fat may deliver new treatments to glioblastoma

In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient's own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor.

13 Mar 2013

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

Researchers have identified a critical protein role in the metastasis of melanoma, the most serious form of skin cancer.

6 Mar 2013

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.

2 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Glioblastoma, the most common and lethal form of brain tumor in adults, is challenging to treat because the tumors rapidly become resistant to therapy. As cancer researchers are learning more about the causes of tumor cell growth and drug resistance, they are discovering molecular pathways that might lead to new targeted therapies to potentially treat this deadly cancer.

27 Feb 2013

Spherical nucleic acids could revolutionize biomedicine

Northwestern University's Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has invented and developed a powerful material that could revolutionize biomedicine: spherical nucleic acids (SNAs).

16 Feb 2013

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.

15 Feb 2013

Castle Biosciences launches MyUvealMelanoma website

Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common form of eye cancer. MyUvealMelanoma tells the story of this disease, its treatment and the importance of prognostic testing, through the experience of patients who recently faced this devastating diagnosis first-hand.

15 Feb 2013

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells for bone marrow protection in the treatment of glioblastoma multiforme.

14 Feb 2013

DelMar announces second closing of $1.5M in private placement

DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.

31 Jan 2013

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

Study finds key association between Kallikrein 6 and malignant tumors

One of the most common types of brain tumors in adults, glioblastoma multiforme, is one of the most devastating. Even with recent advances in surgery, radiation and chemotherapy, the aggressive and invasive tumors become resistant to treatment, and median survival of patients is only about 15 months. In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and the malignant tumors.

18 Jan 2013

ELTD1 biomarker may help diagnose glioma

Researchers using sophisticated genetic testing techniques have identified a promising new biomarker for diagnosis of glioma—the most common type of malignant brain tumor, reports the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Jan 2013

Glioblastoma News and Research

Further Reading

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Patent covering methods of treating ALS receives notice of allowance

NeuroBlate Thermal Therapy System safe for treating recurrent glioblastoma, study shows

Research reveals immortality gene mutation plays pivotal role in brain tumors, other cancers

Diffusion Pharmaceuticals enrolls patients with primary brain cancer in Phase II clinical trial of TSC

Stem cells from patient’s own fat may deliver new treatments to glioblastoma

Targeting ARF6 may be effectively prevent melanoma metastasis to lungs

PDL BioPharma fourth quarter total revenues increase to $86.0 million

EpiCept fourth quarter revenue decreases to $0.1 million

Promyleocytic leukemia gene goes up significantly in post treatment of mTOR inhibitors

Spherical nucleic acids could revolutionize biomedicine

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Castle Biosciences launches MyUvealMelanoma website

FDA grants orphan drug status to Lentigen’s LG631-CD34 for treatment of glioblastoma multiforme

DelMar announces second closing of $1.5M in private placement

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Study finds key association between Kallikrein 6 and malignant tumors

ELTD1 biomarker may help diagnose glioma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News